New hope for Drug-Resistant breast cancer: phase 3 trial launches
NCT ID NCT07354022
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a new drug called HRS-8080, combined with dalpiciclib, works better than the standard treatment (fulvestrant plus dalpiciclib) for people with advanced breast cancer that has become resistant to hormone therapy. About 912 women aged 18-75 with locally advanced or metastatic breast cancer will take part. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-8080 tablet combined with dalpiciclib
What this could lead to
If it works, this could offer a new treatment option for advanced breast cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a large phase 3 trial, but it's still experimental. The new drug may not improve outcomes or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital Fifth Medical Center
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact